Research & Development

Progress for Alzheimer’s following trial presentations

As anticipated, some promising results in the Alzheimer’s field were unveiled at the recently convened congress of the European Federation of Neurological Societies (EFNS), held from 8 to 11 September. Two industry leaders, Pfizer and GE Healthcare, both announced clinical trial results that will undoubtedly impact the current landscape of Alzheimer’s research. There are two major unmet needs that currently plague the field of Alzheimer’s: the lack of therapies that actually target and impact disease progression, and a dearth of early diagnostic biomarkers and imaging tools. Pfizer’s presentation gives new hope for anti-amyloid therapies, showing that they are effective in reducing amyloid and suggesting, as many have thought, that earlier intervention may yield better clinical outcomes, albeit with major side effects. GE Healthcare’s presentation of a novel and effective amyloid imaging agent highlights how the biotech industry is responding to the need for accurate early diagnostic tools for Alzheimer’s.

Poor healthcare policies and infrastructure, but India’s pharma market continues to boom

IndiaIndia has numerous healthcare problems, ranging from inadequate policy monitoring to the widespread lack of health insurance, but a potentially huge, unsaturated market will see the country’s pharmaceutical industry continue to expand rapidly in the coming years, predicts the latest study by GlobalData.

Barriers to overcome in lupus drug development

Lupus

 

There are four main types of lupus: neonatal, discoid (DLE), drug-induced (DIL) and systemic lupus erythmatosus (SLE). When lupus is discussed, most often times it is in reference to SLE as it affects the majority of patients.

Lupus is a chronic autoimmune disease that presents in masquerading ways thus making for difficult and precise diagnosis. 

Breast cancer treatments must adapt for elderly patients

Breast cancer_ribbonThe report* shows that despite many pharmacological treatment options being available for breast cancer treatment, including chemotherapy, hormonal therapy and targeted therapy, patients still fear relapses or resistant tumours.

European Medicines Agency recommends limiting long-term use of calcitonin medicines

CalcitoninThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that calcitonin-containing medicines should only be used for short-term treatment, because of evidence that long-term use of these medicines is associated with an increased risk of cancer.

Would you like to receive our FREE e-newsletter?

* indicates required
Close